How many drugs treat Hodgkin's disease?

Drug Landscape tracks 10 marketed treatments for Hodgkin's disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hodgkin-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hodgkin's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hodgkin's disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hodgkin's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Adcetris	brentuximab-vedotin	Pfizer	CD30-directed Immunoconjugate [EPC]	Tubulin beta	2011-01-01
Gliadel	CARMUSTINE	Avet Lifesciences	Alkylating Drug	Glutathione reductase, mitochondrial	1977-01-01
Gleostine	LOMUSTINE	Azurity	Alkylating Drug [EPC]		1976-01-01
Dtic-Dome	dacarbazine	Bayer	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1975-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Blenoxane	BLEOMYCIN	Bristol-Myers Squibb	Cytoprotective Agent	Aspartyl/asparaginyl beta-hydroxylase	1973-01-01
Matulane	PROCARBAZINE	Leadiant Biosci Inc	Alkylating Drug		1969-01-01
Oncovin	Vincristine Sulfate	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	vincristine	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 5 drugs in Hodgkin's disease
· 4 drugs in Hodgkin's disease
Baxter · 2 drugs in Hodgkin's disease
University of Colorado, Denver · 2 drugs in Hodgkin's disease
Pfizer Inc. · 2 drugs in Hodgkin's disease
Generic (originally Schering) · 2 drugs in Hodgkin's disease
Bristol-Myers Squibb · 1 drug in Hodgkin's disease
Bayer · 1 drug in Hodgkin's disease
Avet Lifesciences · 1 drug in Hodgkin's disease
Generic (originally Merck/Upjohn) · 1 drug in Hodgkin's disease
Generic (originally Upjohn/Pfizer) · 1 drug in Hodgkin's disease
Generic (originally Merck) · 1 drug in Hodgkin's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hodgkin's disease:

Cite this brief

Drug Landscape (2026). Hodgkin's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hodgkin-s-disease. Accessed 2026-06-10.

Hodgkin's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing